Central nervous system effects of GLP-1 receptor agonists: A systematic review of human neuroimaging studies
- 1National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
Abstract
Interest in glucagon-like peptide-1 receptor agonists (GLP-1RAs) has expanded beyond obesity and diabetes, with growing preclinical and clinical evidence supporting potential applications in psychiatric and neurodegenerative disorders. However, the central nervous system (CNS) mechanisms engaged by GLP-1RAs remain poorly characterized, limiting the capacity to optimize their therapeutic potential. This systematic review synthesized the literature examining GLP-1RA-related CNS effects, focusing on treatment-related neural responsivity, temporal dynamics, and modulators of CNS response. PubMed and Embase were systematically searched from inception to January 2026 for human studies across structural magnetic resonance imaging (MRI), task-based and resting-state functional MRI, molecular imaging, and neurophysiological approaches. Thirty-seven studies met inclusion criteria. The reviewed evidence suggests that GLP-1RAs engage distributed cortical and subcortical brain systems. Attenuation of reward-related responsivity following acute GLP-1RA administration was among the more consistent findings. Notably, evidence suggests that GLP-1RAs differentially modulate reward-related processes rather than uniformly attenuate reward function, with neural effects further varying according to metabolic status and underlying phenotype. Several studies additionally indicated that CNS effects evolve over the course of treatment, with more pronounced neural modulation during short-term treatment and diminished or altered effects following prolonged exposure. However, the current neuroimaging literature is constrained by small sample sizes and methodological heterogeneity, limiting direct comparisons across studies and underscoring the need for greater standardization. This review provides insight into the neurobiological mechanisms engaged by GLP-1RAs, identifies emerging patterns of CNS response with potential implications for mechanistically informed treatment strategies, and highlights key mechanistic considerations and priorities for future neuroimaging research.
Related
- Comparison of Five Benzodiazepine-Receptor Agonists on Buprenorphine-Induced μ-Opioid Receptor Regulation
- Association between H19 polymorphisms and susceptibility to pediatric central nervous system tumors in Chinese children
- LightSuite: scalable atlas registration and cell detection across the central nervous system
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
- Oxidative signaling thresholds shape vulnerability in the central and peripheral nervous systems
BibTeX
@article{brucar2026central,
title = {{Central nervous system effects of GLP-1 receptor agonists: A systematic review of human neuroimaging studies}},
author = {Leyla R. Brucar and Kylee B. Miller and Nora D. Volkow},
journal = {Neuroscience and biobehavioral reviews},
year = {2026},
month = sep,
doi = {10.1016/j.neubiorev.2026.106990},
url = {https://doi.org/10.1016/j.neubiorev.2026.106990},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Central nervous system effects of GLP-1 receptor agonists: A systematic review of human neuroimaging studies
AU - Leyla R. Brucar
AU - Kylee B. Miller
AU - Nora D. Volkow
PY - 2026
DA - 2026/09/19
JO - Neuroscience and biobehavioral reviews
DO - 10.1016/j.neubiorev.2026.106990
UR - https://doi.org/10.1016/j.neubiorev.2026.106990
AB - Interest in glucagon-like peptide-1 receptor agonists (GLP-1RAs) has expanded beyond obesity and diabetes, with growing preclinical and clinical evidence supporting potential applications in psychiatric and neurodegenerative disorders. However, the central nervous system (CNS) mechanisms engaged by GLP-1RAs remain poorly characterized, limiting the capacity to optimize their therapeutic potential. This systematic review synthesized the literature examining GLP-1RA-related CNS effects, focusing on treatment-related neural responsivity, temporal dynamics, and modulators of CNS response. PubMed and Embase were systematically searched from inception to January 2026 for human studies across structural magnetic resonance imaging (MRI), task-based and resting-state functional MRI, molecular imaging, and neurophysiological approaches. Thirty-seven studies met inclusion criteria. The reviewed evidence suggests that GLP-1RAs engage distributed cortical and subcortical brain systems. Attenuation of reward-related responsivity following acute GLP-1RA administration was among the more consistent findings. Notably, evidence suggests that GLP-1RAs differentially modulate reward-related processes rather than uniformly attenuate reward function, with neural effects further varying according to metabolic status and underlying phenotype. Several studies additionally indicated that CNS effects evolve over the course of treatment, with more pronounced neural modulation during short-term treatment and diminished or altered effects following prolonged exposure. However, the current neuroimaging literature is constrained by small sample sizes and methodological heterogeneity, limiting direct comparisons across studies and underscoring the need for greater standardization. This review provides insight into the neurobiological mechanisms engaged by GLP-1RAs, identifies emerging patterns of CNS response with potential implications for mechanistically informed treatment strategies, and highlights key mechanistic considerations and priorities for future neuroimaging research.
SN - 0149-7634
SN - 1873-7528
ER -